Publications

Detailed Information

Iron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer's Disease Treatment

DC Field Value Language
dc.contributor.authorJung, Mungyo-
dc.contributor.authorKim, Hyeongseop-
dc.contributor.authorHwang, Jung Won-
dc.contributor.authorChoi, Yejoo-
dc.contributor.authorKang, Mikyung-
dc.contributor.authorKim, Cheesue-
dc.contributor.authorHong, Jihye-
dc.contributor.authorLee, Na Kyung-
dc.contributor.authorMoon, Sangjun-
dc.contributor.authorChang, Jong Wook-
dc.contributor.authorChoi, Suk-Joo-
dc.contributor.authorOh, Soo-Young-
dc.contributor.authorJang, Hyemin-
dc.contributor.authorNa, Duk L.-
dc.contributor.authorKim, Byung-Soo-
dc.date.accessioned2024-06-13T02:10:51Z-
dc.date.available2024-06-13T02:10:51Z-
dc.date.created2023-04-07-
dc.date.created2023-04-07-
dc.date.issued2023-01-
dc.identifier.citationNano Letters, Vol.23 No.2, pp.476-490-
dc.identifier.issn1530-6984-
dc.identifier.urihttps://hdl.handle.net/10371/204224-
dc.description.abstract© 2023 American Chemical Society.Alzheimers disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single pathophysiological mechanism, generally resulting in unsatisfactory therapeutic outcomes. Recently, mesenchymal stem cell (MSC) therapy, which targets multiple pathological mechanisms of AD, has been explored as a novel treatment. However, the low brain retention efficiency of administered MSCs limits their therapeutic efficacy. In addition, autologous MSCs from AD patients may have poor therapeutic abilities. Here, we overcome these limitations by developing iron oxide nanoparticle (IONP)-incorporated human Whartons jelly-derived MSCs (MSC-IONPs). IONPs promote therapeutic molecule expression in MSCs. Following intracerebroventricular injection, MSC-IONPs showed a higher brain retention efficiency under magnetic guidance. This potentiates the therapeutic efficacy of MSCs in murine models of AD. Furthermore, human Whartons jelly-derived allogeneic MSCs may exhibit higher therapeutic abilities than those of autologous MSCs in aged AD patients. This strategy may pave the way for developing MSC therapies for AD.-
dc.language영어-
dc.publisherAmerican Chemical Society-
dc.titleIron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer's Disease Treatment-
dc.typeArticle-
dc.identifier.doi10.1021/acs.nanolett.2c03682-
dc.citation.journaltitleNano Letters-
dc.identifier.wosid000920395300001-
dc.identifier.scopusid2-s2.0-85146397154-
dc.citation.endpage490-
dc.citation.number2-
dc.citation.startpage476-
dc.citation.volume23-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorKim, Byung-Soo-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusANGIOGENESIS-
dc.subject.keywordPlusEXPRESSION-
dc.subject.keywordPlusMODEL-
dc.subject.keywordAuthorMesenchymal stem cells-
dc.subject.keywordAuthoriron oxide nanoparticles-
dc.subject.keywordAuthormagnetic guidance-
dc.subject.keywordAuthorAlzheimer?s disease-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Engineering
  • School of Chemical and Biological Engineering
Research Area biomaterials, nanomedicine, regenerative medicine

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share